Showing 1159 Results
CMS hosted patient-focused listening sessions to discuss the first 10 drugs selected for the Medicare Drug Price Negotiation Program. In this analysis, NPC offers three takeaways to inform how the…
NPC writes in Health Affairs Forefront about the unintended consequences of the IRA and the impact of the changing economic incentives for clinical development programs.
The drug price-related provisions of the Inflation Reduction Act make the case for including dynamic drug pricing in cost-effectiveness analysis even more compelling.
Michael Pratt named Chief Communications Officer as NPC boosts research and engagement capabilities